Ultrasonographic Tissue Thickness After Complex Decongestive Therapy in Lower-Limb Lymphedema
Effect of Complex Decongestive Therapy on Subcutaneous Tissue Thickness in Lower-Limb Lymphedema: A Prospective Ultrasonographic Study With Contralateral Internal Control
This prospective single-center study evaluated whether 4 weeks of phase-1 complex decongestive therapy (manual lymphatic drainage, multilayer short-stretch bandaging, decongestive exercise, and skin care) changes dermal and subcutaneous tissue thickness measured by high-frequency ultrasonography in adults with unilateral International Society of Lymphology stage 1-2 lower-limb lymphedema. Measurements were made at suprapatellar and infrapatellar sites of both limbs before and after treatment; the unaffected limb served as an internal control and body weight was recorded to distinguish local tissue change from systemic weight change.
調査の概要
詳細な説明
Participants received a standardized 20-session (5 days/week, 4 weeks) intensive-phase complex decongestive therapy program delivered by an experienced physiotherapist. Ultrasonographic measurements were performed with a 10-14 MHz linear probe using a minimal-compression technique after 15 minutes of supine rest, at the same time of day, by an assessor blinded to baseline values; intra-rater reliability (intraclass correlation coefficient 0.92) was established in 10 patients. The sample size (n = 34; Cohen's d = 0.5, power 80%, alpha 0.05; 40 recruited) was calculated with G*Power. Paired comparisons (paired t-test or Wilcoxon signed-rank test), 95% confidence intervals, Cohen's d, and Pearson correlation of treatment response with age, body mass index, and disease duration were planned.
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
-
Kayseri、トルコ(Türkiye)、38080
- Kayseri City Training and Research Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Adults presenting to the Physical Medicine and Rehabilitation outpatient clinic of Kayseri City Hospital with unilateral lower-limb lymphedema and an indication for intensive-phase complex decongestive therapy.
説明
Inclusion Criteria:
- Age 18 years or older
- Unilateral lower-limb lymphedema, International Society of Lymphology stage 1 or 2 (2020 consensus)
- Diagnosis supported by lymphoscintigraphy
- Indication for intensive-phase complex decongestive therapy
- No previous full course of complex decongestive therapy on the affected limb
- Written informed consent
Exclusion Criteria:
- Active cellulitis or erysipelas at the measurement sites
- Active, recurrent, or metastatic malignancy
- Decompensated heart failure or history of deep vein thrombosis
- Bilateral lymphedema
- Cognitive impairment preventing adherence to treatment
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:PROSPECTIVE
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
Lower-limb lymphedema, complex decongestive therapy
Adults with unilateral ISL stage 1-2 lower-limb lymphedema who received 4 weeks (20 sessions) of phase-1 complex decongestive therapy as standard care. Dermal and subcutaneous tissue thickness were measured by high-frequency ultrasonography at suprapatellar and infrapatellar sites of both limbs before and after treatment; the unaffected limb served as an internal control. |
Phase-1 (intensive) complex decongestive therapy delivered 5 days per week for 4 weeks (20 sessions) by an experienced physiotherapist: Vodder-technique manual lymphatic drainage (30-45 min), multilayer short-stretch compression bandaging from the toes to the proximal thigh, decongestive range-of-motion exercise performed with bandages in place, and daily skin care with a pH 5.5 moisturizer.
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in subcutaneous tissue thickness of the affected limb at the suprapatellar site
時間枠:Baseline and end of week 4 (after 20 sessions of complex decongestive therapy)
|
Subcutaneous tissue thickness (dermis-subcutis interface to deep fascia) measured in millimeters by B-mode ultrasonography with a 10-14 MHz linear probe using a minimal-compression technique. |
Baseline and end of week 4 (after 20 sessions of complex decongestive therapy)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in subcutaneous tissue thickness of the affected limb at the infrapatellar site
時間枠:Baseline and end of week 4
|
Subcutaneous tissue thickness in millimeters measured by B-mode ultrasonography (10-14 MHz linear probe, minimal-compression technique). |
Baseline and end of week 4
|
|
Change in dermal thickness of the affected limb at the suprapatellar and infrapatellar sites
時間枠:Baseline and end of week 4
|
Dermal thickness (skin surface to dermis-subcutis interface) in millimeters measured by B-mode ultrasonography. |
Baseline and end of week 4
|
|
Change in subcutaneous tissue thickness of the unaffected (control) limb
時間枠:Baseline and end of week 4
|
Subcutaneous tissue thickness of the contralateral unaffected limb at the suprapatellar and infrapatellar sites, in millimeters, measured by B-mode ultrasonography; serves as an internal control. |
Baseline and end of week 4
|
|
Change in body weight
時間枠:Baseline and end of week 4
|
Body weight in kilograms measured on the same calibrated scale, recorded to distinguish local tissue change from systemic weight change. |
Baseline and end of week 4
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Correlation of subcutaneous thickness change with disease duration, age, and body mass index
時間枠:Baseline and end of week 4
|
Pearson correlation coefficients between the change in suprapatellar subcutaneous thickness of the affected limb and disease duration (months), age (years), and body mass index (kg/m2). |
Baseline and end of week 4
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Abdullah Goktug Yazar, MD、Kayseri City Hospital
- スタディチェア:Ayse Guc, MD、Kayseri City Hospital
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 2025-491
- 491 (その他の識別子:Kayseri City Hospital Clinical Research Ethics Committee)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。